Group 1 - Guerbet has appointed Mr. Karim Boussebaa as Chief Executive Officer, effective February 2, 2026, following a decision by the Board of Directors [2][4] - Mr. Boussebaa has over 25 years of international experience in healthcare and medical technology, with a strong background in medical imaging and medical devices [3] - The appointment aims to strengthen Guerbet's operational and strategic management to adapt to a rapidly evolving market environment [4] Group 2 - Mr. Hugues Lecat, Chairman of the Board, emphasized the importance of Mr. Boussebaa's leadership in supporting the company's strategy and performance [4] - Mr. Jérôme Estampes will return to his role as Group Chief Financial Officer and SVP Business Development & Licensing after serving as interim CEO [5] - Guerbet reported €841 million in revenue for 2024 and dedicates 9% of its revenue to Research & Development [7]

Board Composition Changes - Guerbet's Annual General Meeting voted to reduce the terms of office of directors from six years to four years to comply with the Afep-Medef Code of corporate governance [2][9] - The terms of office for Claire Jouault Massiot, Céline Lamort, Mark Fouquet, Didier Izabel, and Jean-Sebastien Raynaud expired at the Annual General Meeting, and Pascale Auger resigned as a director [3][11] - Two new directors were appointed, Michèle Lesieur and Eric Drapé, while Céline Lamort and Marc Massiot were re-elected, bringing the total number of directors to nine [3][10][11] New Appointments - Michèle Lesieur was appointed as an independent director for a three-year term, bringing extensive experience in the healthcare sector, including leadership roles at Philips and Supersonic Imagine [4][5] - Eric Drapé was appointed as an independent director for a four-year term, with over 35 years of experience in the pharmaceutical industry, including senior positions at Teva Pharmaceuticals and Ipsen Pharma [6][7] Board Structure - The current Board of Directors consists of nine members, including three independent directors: Hugues Lecat, Eric Drapé, and Michèle Lesieur [11][12] - The Board expressed gratitude to outgoing directors for their contributions and welcomed the new appointees [11] Company Overview - Guerbet is a leader in medical imaging, offering a range of pharmaceutical products, medical devices, and digital solutions, with a revenue of €841 million in 2024 [13] - The company invests 9% of its sales in research and development across four centers in France and the United States [13]